tradingkey.logo

BRIEF-Madrigal Announces Two-Year Data From The Compensated Mash Cirrhosis Arm Of The Maestro-Nafld-1 Trial

ReutersFeb 26, 2025 12:52 PM

- Madrigal Pharmaceuticals Inc MDGL.O:

  • MADRIGAL ANNOUNCES NEW TWO-YEAR DATA FROM THE COMPENSATED MASH CIRRHOSIS ARM OF THE MAESTRO-NAFLD-1 TRIAL DEMONSTRATING POTENTIAL BENEFIT OF REZDIFFRA™ (RESMETIROM) IN PATIENTS WITH COMPENSATED MASH CIRRHOSIS

  • MADRIGAL PHARMACEUTICALS INC - REPORTS POSITIVE TWO-YEAR RESULTS FROM PHASE 3 TRIAL

  • MADRIGAL PHARMACEUTICALS INC - SAFETY PROFILE OF REZDIFFRA CONSISTENT WITH OTHER TRIALS

Source text: ID:nGNXbShBP0

Further company coverage: MDGL.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI